Literature DB >> 12415361

Sacrococcygeal teratoma.

Ashish Wakhlu1, Sanjeev Misra, R K Tandon, A K Wakhlu.   

Abstract

This retrospective study details our experience regarding 72 patients with sacrococcygeal teratoma treated over a period of 17 years. The sex incidence was nearly equal, but there was a high proportion of Altmann type IV tumors. A preliminary colostomy before combined abdominosacral excision of large type III and IV lesions reduced morbidity. Sixty-six percent of the patients presented beyond the neonatal period; 14 had been treated elsewhere for bowel/urinary obstruction. Imaging studies included radiography, abdominal ultrasound, computed tomography, and magnetic resonance imaging (after 1995). In 60 patients the tumor was excised via the sacral route, 11 had a preliminary colostomy, and 1 had a vesicostomy. Eight children (5 with malignant lesions) required abdominosacral excision. After 1990, serial estimation of serum alpha-fetoprotein (AFP) was used to monitor tumor recurrence. There were 34 male and 38 female patients (age range 3 days-12 years); 47 had benign tumors, of which 42 were excised through the sacral route. Three patients underwent a preliminary colostomy and abdominosacral excision of the tumor with subsequent colostomy closure. There were 4 deaths in this group; no recurrence was seen in the surviving children with benign tumors. Twenty-five patients had malignant teratomas. In 18 of these the tumor was excised via the sacral route and 5 underwent abdominal-sacral excision. Eight had a preliminary colostomy and chemotherapy followed by excision of the residual tumor and colostomy closure. None of the initial 14 patients with malignant lesions survived beyond 2 years. Of the latter 11 (who received cisplatinum-based chemotherapy), 10 were alive 1 year after surgery. One patient is currently on preoperative chemotherapy and another developed recurrence of the tumor. The overall follow-up ranged from 3 months to 8 years; there has been no complaint of functional neurological deficit in any of the patients. As intrapelvic tumors tend to have a delayed diagnosis, this can be avoided by performing a rectal examination. There should be no recurrence after excision of a benign teratoma. Cisplatinum-based chemotherapy has improved the survival of patients with malignant tumors.

Entities:  

Mesh:

Year:  2002        PMID: 12415361     DOI: 10.1007/s00383-002-0729-z

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  7 in total

1.  Clinicopathological Evaluation of Childhood Sacrococcygeal Germ Cell Tumors: A Single-Center Experience.

Authors:  Bermal Hasbay; Tuba Canpolat; Elif Aktekin; Hasan Özkan; Şenay Demir Kekeç
Journal:  Turk Arch Pediatr       Date:  2022-05

2.  Sacrococcygeal teratoma in Northeastern Nigeria: 18-years experience.

Authors:  A M Abubakar; H A Nggada; J Y Chinda
Journal:  Pediatr Surg Int       Date:  2005-10-13       Impact factor: 1.827

3.  Somatic malignant transformation in a sacrococcygeal teratoma in a child and the use of F18FDG PET imaging.

Authors:  R Howman-Giles; A J A Holland; D Mihm; J M Montfort; S Arbuckle; S Kellie
Journal:  Pediatr Surg Int       Date:  2007-09-09       Impact factor: 1.827

4.  Sacrococcygeal teratoma.

Authors:  Vivek Gharpure
Journal:  J Neonatal Surg       Date:  2013-04-01

5.  Neonatal sacrococcygeal teratoma: our experience with 10 cases.

Authors:  Shalini Sinha; Yogesh Kumar Sarin; Vidyanand P Deshpande
Journal:  J Neonatal Surg       Date:  2013-01-01

6.  Prenatal and Neonatal MRI of Sacrococcygeal Teratoma With Surgical Correlation.

Authors:  Ali Mahmood; Nadia F Mahmood
Journal:  Radiol Case Rep       Date:  2015-12-07

7.  Surgical treatment of a type IV cystic sacrococcygeal teratoma with intraspinal extension utilizing a posterior-anterior-posterior approach: a case report.

Authors:  Aaron Wessell; David S Hersh; Cheng-Ying Ho; Kimberly M Lumpkins; Mari L A Groves
Journal:  Childs Nerv Syst       Date:  2018-01-24       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.